+44 115 7870500
DevelRx Logo
Research & Candidate SelectionDrug DevelopmentRegistrationMarketing
News & EventsPartnersContact

Scientific Articles - Drug abuse and dependence

Drug Abuse and DependenceADHDBinge-Eating DisorderPsychiatric and Neurological DisordersObesity and Metabolic Disorders

Smith SL, Dean RL, Todtenkopf MS, Heal DJ. I[nvestigation of the reinforcing potential of samidorphan and naltrexone by fixed and progressive ratio intravenous self-administration testing in heroin-maintained rats.](https://pubmed.ncbi.nlm.nih.gov/30676189/?from_term=heal+D&from_sort=date&from_pos=5) J Psychopharmacol, 2019; 33: 383-391.

Wright VL, Georgiou P, Bailey A, Heal DJ, Bailey CP, Wonnacott S. Inhibition of α7 nicotinic receptors in the ventral hippocampus selectively attenuates reinstatement of morphine-conditioned place preference and associated changes in AMPA receptor binding. Addict Biol, 2019; 24: 590-603.

Heal DJ, Henningfield J, Frenguelli BG, Nutt DJ, Smith SL. [Psychedelics - Re-opening the doors of perception.](https://pubmed.ncbi.nlm.nih.gov/30144477/?from_term=heal+D&from_sort=date&from_pos=7)  Neuropharmacol, 2018; 142: 1-6.

Heal DJ, Gosden J, Smith SL. [Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans.](https://pubmed.ncbi.nlm.nih.gov/29427652/?from_term=heal+D&from_sort=date&from_pos=9)  Neuropharmacol, 2018; 142: 89-115.

Calderon S, Giarola A, Heal D. Regulatory Framework and Guidance to the Evaluation of the Abuse Liability of Drugs in the United States and Europe. In: Markgraf CG, Hudzik TJ, Compton DR (Eds). Nonclinical Assessment of Abuse Potential for New Pharmaceuticals. Academic Press, pp. 245–268, 2015.

Heal DJ, Smith SL, Henningfield JE. CNS stimulants. Neuropharmacol, 2014; 87: 1-3.

Heal DJ, Gosden J, Smith SL. Dopamine reuptake transporter (DAT) "inverse agonism" - A novel hypothesis to explain the enigmatic pharmacology of cocaine. Neuropharmacol, 2014; 87: 19-40.

Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine, past and present – A pharmacological and clinical perspective. J Psychopharmacol, 2013; 27: 479-496.

Heal DJ, Buckley NW, Gosden J, Slater N, France CP, Hackett D. A preclinical evaluation of the discriminative and reinforcing properties of lisdexamfetamine in comparison to D-amfetamine, methylphenidate and modafinil. Neuropharmacol, 2013; 73: 348-58.

Rowley HL, Kulkarni R, Gosden J, Brammer R, Hackett D, Heal DJ. Lisdexamfetamine and immediate-release d-amfetamine - differences in pharmacokinetic/pharmacodynamic relationships revealed by striatal microdialysis in freely-moving rats with simultaneous determination of plasma drug concentrations and locomotor activity. Neuropharmacol, 2012; 63: 1064-74.

Kennett A, Heal DJ, Wonnacott S. Pharmacological differences between rat frontal cortex and hippocampus in the nicotinic modulation of noradrenaline release implicate distinct receptor subtypes. Nicotine Tob Res, 2012; 14: 1339-45.

Freeman KB, Heal DJ, McCreary AC, Woolverton WL. Assessment of ropinirole as a reinforcer in rhesus monkeys. Drug Alcohol Depend, 2012; 125: 173-7.

Sidhpura N, Redfern P, Rowley H, Heal D and Wonnacott S. Comparison of the effects of bupropion and nicotine on locomotor activation and dopamine release in vivo. Biochem Pharmacol, 2007; 74: 1292-8.

DevelRx Logo


Pennyfoot Street,





Cookie PolicyPrivacy PolicyTerms & Conditions

Registered in England and Wales

Company number: 12028847